Concise Communication

Impact of the Ebola Epidemic on General and HIV Care in Macenta, Forest Guinea, 2014

Short title

Ebola Impact on HIV Care in Guinea

Authors

David LEUENBERGER[1], Jean HEBELAMOU[1], Stefan STRAHM[1], Nathalie DE REKENEIRE[2,3], Eric BALESTRE[2,3], Gilles WANDELER[4,5], François DABIS[2,3], for the IeDEA (International epidemiological databases to evaluate AIDS) West Africa study group

Author affiliations

1. Centre Médical de Macenta, Mission Philafricaine, Conakry, Guinea
2. INSERM U897 – Centre Inserm Epidémiologie et Biostatistique, Université de Bordeaux, Bordeaux, France
3. Université de Bordeaux, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, Bordeaux, France
4. Department of Infectious Diseases, University Hospital Bern, Bern, Switzerland
5. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

Word count: 1795

Corresponding author / requests for reprints

Dr David Leuenberger
Mission Philafricaine, B.P. 214, Conakry 1, Rép. de Guinée
david.leuenberger@sam-ame.org

Funding

The National Cancer Institute (NCI), the Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) and the National Institute of Allergy and Infectious Diseases (NIAID) of the U.S. National Institutes of Health (NIH), as part of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) under Award Number U01AI069919.

Disclaimer

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Supplemental Digital Content 3

Table. Factors associated with attrition (death or loss to follow-up) estimated with Cox regression models within HIV patients enrolled into care in the Macenta cohort in the first semesters of 2013 and 2014 (n=389)

Variables	Univariable models		Final multivariable model	
	HR† (CI‡ 95%)	p-value	HR (CI 95%)	p-value
Year of enrolment		0.4320		0.9313
2013	1		1	
2014	0.88 (0.65;1.20)		1.02 (0.72;1.43)	
Geographical origin*		0.5679		
Macenta city	1			
Macenta district	1.20 (0.86;1.66)			
Outside Macenta district	1.09 (0.73;1.63)			
Mode of entry		0.4453		
New diagnosis	1			
Transfer in (on ART or not)	0.84 (0.53;1.33)			
Gender		0.2579		
Female	1			
Male	1.19 (0.88;1.60)			
Age (years) at enrolment		0.8995		
[0-16[	0.82 (0.38;1.78)			
[16-30[	1			
[30-40[	1.10 (0.77;1.56)			
[40-50[	0.92 (0.61;1.40)			
≥50	0.93 (0.57;1.53)			
Tuberculosis (TB)		0.266		0.0341
No TB	1		1	
TB at enrolment	1.50 (1.05;2.14)		1.55 (1.03;2.31)	
Initial WHO stage		0.0421		0.0348
WHO I, II	1		1	
WHO III	1.52 (1.08;2.13)		1.64 (1.12;2.39)	
WHO IV	1.67 (1.03;2.72)		2.01 (1.16;3.48)	
Missing	2.03 (0.96;4.29)		1.73 (0.79;3.81)	
Initial CD4 count (/mm^3)		<0·0001		<0.0001
0-49	1.73 (1.01;2.96)		3.15 (1.70;5.82)	
50-199	1.26 (0.77;2.06)		2.55 (1.47;4.42)	
200-349	0.87 (0.51;1.50)		2.27 (1.22;4.19)	
350-499	1.06 (0.58;1.91)		1.58 (0.86;2.90)	
≥500	1		1	
Missing	3.43 (2.11;5.58)		4.09 (2.45;6.84)	
Cotrimoxazole prophylaxis		0.5226		
After enrolment	1			
Prior to enrolment	0.87 (0.55;1.36)			
No cotrimoxazole	0.76 (0.45;1.29)			
Antiretroviral therapy (ART)		<0.0001		<0.0001
≤2 months after enrolment	1		1	
>2 months after enrolment	0.41 (0.20;0.85)		0.54 (0.26;1.15)	
Prior to enrolment	1.09 (0.67;1.77)		1.11 (0.66;1.86)	
Not ART-treated	2.68 (1.95;3.67)		4.67 (3.13;6.97)	

†Hazard ratio. ‡Confidence interval at 95%. *1 patient was excluded from this univariable model because origin was missing.

ART, Antiretroviral therapy, TB, Tuberculosis, WHO, World Health Organization.